These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 30685871)

  • 21. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
    Goldmann L; Duan R; Kragh T; Wittmann G; Weber C; Lorenz R; von Hundelshausen P; Spannagl M; Siess W
    Blood Adv; 2019 Dec; 3(23):4021-4033. PubMed ID: 31809536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
    Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI.
    Wijeyewickrema LC; Gardiner EE; Moroi M; Berndt MC; Andrews RK
    Thromb Haemost; 2007 Dec; 98(6):1285-90. PubMed ID: 18064326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
    Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
    J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
    Bhatti M; Ayton S; Michail O; Gollop ND; Ryding A; Rushworth S; Bowles K; Geisler T; Flather M
    Thromb Res; 2019 Jul; 179():64-68. PubMed ID: 31082751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
    Tullemans BME; Karel MFA; Léopold V; Ten Brink MS; Baaten CCFMJ; Maas SL; de Vos AF; Eble JA; Nijziel MR; van der Vorst EPC; Cosemans JMEM; Heemskerk JWM; Claushuis TAM; Kuijpers MJE
    EJHaem; 2021 Nov; 2(4):685-699. PubMed ID: 35845214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
    Wu J; Zhang M; Liu D
    J Hematol Oncol; 2016 Mar; 9():21. PubMed ID: 26957112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
    Yu H; Truong H; Mitchell SA; Liclican A; Gosink JJ; Li W; Lin J; Feng JY; Jürgensmeier JM; Billin A; Xu R; Patterson S; Pagratis N
    SLAS Discov; 2018 Oct; 23(9):919-929. PubMed ID: 30011241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.
    Duan R; Goldmann L; Li Y; Weber C; Siess W; von Hundelshausen P
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H; Kryštof V
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
    Chen J; Kinoshita T; Gururaja T; Sukbuntherng J; James D; Lu D; Whang J; Versele M; Chang BY
    Eur J Haematol; 2018 Jul; ():. PubMed ID: 30030853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 40. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
    Estupiñán HY; Wang Q; Berglöf A; Schaafsma GCP; Shi Y; Zhou L; Mohammad DK; Yu L; Vihinen M; Zain R; Smith CIE
    Leukemia; 2021 May; 35(5):1317-1329. PubMed ID: 33526860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.